---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-086035"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2023-08-01T23:59:59+00:00"
generated_at: "2026-06-12T18:34:19.791881+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Entrada Therapeutics gets UK authorization to start Phase 1 trial of ENTR-601-44 for Duchenne

## Summary
- UK MHRA and REC authorized Phase 1 CTIMP for ENTR-601-44 in healthy volunteers for exon 44 skipping Duchenne.
- Phase 1 will enroll ~40 participants; primary endpoint safety, plus tolerability, PK, and exon skipping in muscle.
- First participant expected to be dosed September 2023; data anticipated in second half of 2024.
- Cash runway extended through end of 2025, supporting Duchenne franchise and broader intracellular therapeutics.
- ENTR-601-44 is lead Duchenne product candidate for patients amenable to exon 44 skipping.

## SEC filing metadata
- accession: 0001104659-23-086035
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2023-08-01T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000110465923086035/0001104659-23-086035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000110465923086035/tm2322453d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-086035
- JSON: https://secwatch.observer/filing/0001104659-23-086035.json
- Plain text: https://secwatch.observer/filing/0001104659-23-086035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.